
Stock chart
Analyses on Bioline (4)
- April 28, 2026
- March 23, 2026March 23, 2026
- Follow-up
From APHEXDA to cash: how much of BioLineRx’s partnership economics can really turn into clean liquidity
APHEXDA's partnerships give BioLineRx meaningful economic upside, but as of year-end 2025 the gap between headline economics and clean liquidity remains wide: part of the historical cash arrived together with equity issuance, the recurring stream is still small, and part of futu…

- Follow-up
GLIX1 and Tetragon: how much of the balance-sheet uplift is accessible value and how much is deal structure
The GLIX1 deal with Hemispherian strengthened BioLineRx’s consolidated balance sheet, but at the starting point it created mainly accounting control and an economic option, not fully accessible value for common shareholders. The $6.0 million intangible asset was booked against n…

BioLineRx 2025: the loss nearly disappeared, but the funding test is only starting
BioLineRx has moved from an expensive commercialization model to a leaner royalty-and-development model, but 2025 mainly bought time rather than solved the economics: recurring revenue is still tiny, GLIX1 adds both upside and funding needs, and the proof of sustainability is st…













